A role for proteinase-activated receptor-4 (PAR-4) was recently suggested in itch sensation.
Introduction
Itch is a common symptom of dermatological and systemic diseases such as atopic dermatitis and cholestasis (Ikoma et al., 2006) . Chronic itching remains without satisfactory treatment and lowers patients' quality of life (Weisshaar et al., 2006) . Studies using pruritogenic spicules obtained from cowhage (Mucuna pruriens) have revealed the existence of pruriceptive afferents distinct from the well-known histaminergic pathway (Davidson et al., 2007; Johanek et al., 2007; Namer et al., 2008) . The active component of cowhage is mucunain, a cysteine protease which acts as an activator of protease-activated receptors (PARs) (Reddy et al., 2008; Shelley and Arthur, 1955) . PARs are a subfamily of G-protein coupled receptors, named PAR-1 to 4, that are activated by the proteolytic cleavage of their extracellular domain (Vergnolle, 2009) .
With the discovery of PAR-2 involvement in itch, great progress has been made in terms of understanding the pathophysiological basis of itching (Steinhoff et al., 2003) . PAR-2 (Costa et al., 2010; Costa et al., 2008) and, more recently, PAR-4 (Kempkes et al., 2014) were suggested to mediate itch. PAR-4 is expressed on rodent sensory neurons (Asfaha et al., 2007; Auge et al., 2009 ) and can be activated by several endogenous proteinases and synthetic hexapeptides (Fu et al., 2014) . Interestingly, the itch-causing agent mucunain cleaves PAR-4 more potently than PAR-2 (Reddy et al., 2008) . Furthermore, it was shown that cathepsin S, an endogenous cysteine protease that shares sequence homology with the mucunain active site, evokes itch in humans via activation of both PAR-2 and -4 (Reddy et al., 2010) . Indeed, intradermal (i.d.) injection of PAR-4 agonists caused scratching behavior in mice (Akiyama et al., 2010; Akiyama et al., 2009; Tsujii et al., 2008) .
Although evidences suggest a role for PAR-4 in itch, the signaling mechanisms involved in this process are poorly understood. Here, we investigated the cellular and molecular mechanisms associated with the scratching behavior induced by the PAR-4-activating peptide AYPGKF-NH 2 (AYP) in mice, and provided data supporting the role of PAR-4 in itch. We show that AYP elicits scratching behavior in mice by activating transient receptor potential (TRP) channels and possibly causing the release of itch-mediating neurotransmitters. These findings highlight the potential of PAR-4 as a target for the development of antipruritic drugs.
Results

PAR-4 activation induces scratching behavior in mice
I.d. administration of the selective PAR-4 agonist AYP, but not the inactive peptide YAPGKF-NH 2 (YAP), elicited scratching behavior when injected into the back of the mouse neck ( Figure 1a ) with an effective dose ranging from 100 to 500 nmol/site and an estimated mean ED 50 value (accompanied by 95% confidence limit) of 156 (42 -572) nmol/site. The dose of 200 nmol/site was chosen for all the subsequent experiments. AYP-induced scratching behavior was time-dependent, peaking within 10 minutes and decreasing slowly over time, without a significant response at 30 minutes ( Figure 1b ). Interestingly, the number and the time-course profiles of AYP-evoked scratching bouts were similar to those caused by histamine (Figures 1a,   b ), a widely known pruritogenic agent. As expected, pre-treatment with the selective PAR-4 antagonist pepducin P4pal-10 significantly reduced AYP-induced scratching behavior ( Figure   1c ). In addition, pre-treatment with the non-selective opioid receptor antagonist naloxone, used as an antipruritic control drug, also significantly inhibited AYP-induced response (Figure 1d ).
AYP-induced scratching behavior is dependent on GRP-expressing fibers
We found PAR-4 to be expressed in ~32% of all mouse skin mast cells and AYP (200 nmol/site) i.d. injection was able to cause mast cell degranulation; however, AYP-induced itch was not dependent on mast cell products release (Supplementary results and Figure S1 ).
Additionally, we detected PAR-4 on skin sensory neurons as PAR-4 immunoreactivity was co-localized with the neuronal marker PGP 9.5 (Figure 2a, b ). PAR-4 was also found in the soma of 47% of mouse dorsal root ganglion (DRG) neurons (247/525). Of those, 39% (95/247), 34% (85/247) and 27% (67/247) were small-, medium-and large-diameter neurons, respectively. To investigate the phenotype of PAR-4-expressing neurons, we performed a double-labeling for PAR-4 and gastrin-releasing peptide (GRP), a marker of pruriceptive neurons (Sun and Chen, 2007) . Interestingly, 77% (191/247) of all PAR-4-positive cells were co-localized with GRP, and 87% of the GRP-positive cells (184/212) expressed PAR-4 ( Figure 2c ). The functional relevance of GRP-containing neurons for PAR-4-mediated scratching behavior was then investigated in animals pre-treated with the selective GRP receptor (GRPR) antagonist RC-3095. Of relevance, scratching behavior was significantly prevented by RC-3095 administration (Figure 2d ).
AYP stimulates TRP channel-expressing DRG neurons
To determine whether AYP has direct effects on primary sensory neurons we performed live-cell calcium imaging. Interestingly, AYP (200 µM) evoked an increase in intracellular calcium concentration ([Ca 2+ ] i ) in only 1.5% (170/11,273) of the DRG neurons from wild-type mice ( Figure 3 ). In order to investigate whether PAR-4 was localized to TRP channel-expressing DRG neurons, cells were challenged sequentially with AYP (200 µM), the TRPA1 agonist allyl isothiocyanate (AITC; 50 µM) and the TRPV1 agonist capsaicin (1 µM), followed by KCl (50 mM). Of all AYP-sensitive neurons, 54.2% (70/129) were responsive to both capsaicin and AITC ( Figure 3a ), while 31% (40/129) and 11.6% (15/129) were responsive to only capsaicin ( Figure   3b ) or AITC (Figure 3c ), respectively. Consequently, 96.9% (125/129) of the AYP-sensitive neurons were sensitive to either capsaicin or AITC, and 3.1% (4/129) of AYP-responsive neurons were insensitive to these agonists.
We next examined the responses of DRG neurons from TRPV1 (Trpv1 -/-) or TRPA1 (Trpa1 -/-) knockout mice to AYP. Notably, the responses to AYP were eliminated in the Trpv1 -/neurons in comparison with neurons from wild-type animals (0/2,363 neurons; p<0.0001, Chi squared test). However, no reduction was observed in the percentage of AYP-responsive neurons from Trpa1 -/mice (1.97%; 54/2,745 neurons) where the proportion of AYP-responsive neurons was slightly higher than in wild-type neurons (P<0.05, Chi squared test). Notably, almost all AYP-sensitive Trpa1 -/neurons (53/54) responded to capsaicin, consistent with the findings in preparations from wild-type mice (Figure 3d ).
PAR-4-mediated scratching behavior requires TRP channel activation and SP release
We investigated the functional involvement of TRP channels in AYP-induced scratching behavior. TRPV1 and TRPA1 are expressed in sensory afferents neurons and are involved in itch transmission (Imamachi et al., 2009; Wilson et al., 2011) . The importance of these channels was assessed in animals pre-treated with either the selective TRPV1 (SB366791) or TRPA1 (HC-030031) receptor antagonists. Results show that both antagonists were able to alleviate AYPinduced scratching behavior by 61% and 55%, respectively (Figure 4a, b) . Similarly, itch was attenuated in AYP-treated Trpv1 -/mice in comparison with their WT counterparts ( Figure 4c ). In contrast, TRPA1 deletion appeared to increase the scratching response evoked by AYP, although this was not statistically significant ( Figure 4c ).
Discussion
In the present study, we provide evidence that PAR-4 mediates scratching behavior in mice by activating TRP channels and possibly causing the release of GRP and SP. A role for PAR-4 in itch was first suggested by Tsujii and collaborators (2008) who demonstrated that AYP elicits scratching behavior in mice at the dose of 100 nmol/site. Curiously, in a study performed by the same group in 2009, AYP at the same dose, failed to cause a pruriceptive response in mice (Tsujii et al., 2009 ). These discrepant results may be due to the use of different strains of mice of different ages in these studies. Here, scratching behavior was elicited by AYP injection in the nape of the neck and it was inhibited by the selective PAR-4 antagonist (confirming AYP selectivity) and by naloxone, a centrally acting opioid receptor antagonist used to treat some clinical itch conditions (Phan et al., 2010) . Indeed, AYP-induced hindpaw scratching bouts had been previously described in the same model (Akiyama et al., 2009) and later confirmed in the cheek model of itch (Akiyama et al., 2010) and in the alloknesis model (Akiyama et al., 2012) .
Both human and rat mast cells can express PAR-4 (Han et al., 2011; Russell et al., 2011) , and mast cells are considered to be central in some itching conditions . However, the contribution of histamine to AYP-induced itch is rather controversial, with evidence suggesting this response to be dependent on (Tsujii et al., 2008) and independent of (Akiyama et al., 2009; Tsuji et al., 2009) this pathway. Here, we show that PAR-4 is also expressed on mouse mast cells and that AYP has the ability to cause their degranulation.
However, we present evidence that AYP elicits itch in a mast cell-independent manner, with neither mast cells nor their mediators playing a role in this response. It is important to highlight that the discrepancies observed between our study and previous studies addressing the contribution of histamine to AYP-induced itch may be related to differences in mouse strain, gender and/or age and differences in AYP dose; in addition to the use of different strategies to investigate histamine contribution to this response.
We also present evidence that PAR-4 is expressed on sensory neurons innervating the mouse skin, as confirmed by its co-localization with the neuronal marker PGP 9.5. PAR-4 was previously detected on the rat DRG neurons co-localized with neuropeptides such as SP (Asfaha et al., 2007) . Herein, PAR-4 was found in the soma of small-to large-sized DRG neurons. We found that 77% of all PAR-4-positive neurons contain the pruriceptive marker GRP and 87% of all GRP-positive cells also express PAR-4. GRP can be found in peptidergic fibers innervating the mouse skin (Tominaga et al., 2009) and in small-to medium-sized DRG neurons which also express SP and TRPV1 (Sun and Chen, 2007) . Although still debatable (Bautista et al., 2014) , GRP-dependent pruriceptive pathway is composed of peptidergic C-fibers containing GRP and by GRPR in the spinal cord. The genetic deletion or antagonism of GRPR, as well as the depletion of GRP-positive fibers, was able to prevent pruritus in mice (Sun and Chen, 2007; Sun et al., 2009) . Corroborating these findings, the systemic treatment with the selective GRPR antagonist RC-3095, prevented AYP-induced scratching behavior, suggesting that this response involves the release of GRP. This compound is known for its ability to cross the blood brain barrier (BBB) (Andoh et al., 2011) , thus, it is possible that spinal cord located GRPR contribute to AYP-induced itch.
We hypothesized that AYP induces itch by activating PAR-4 on skin pruriceptive fibers with cellular bodies in the DRG. Surprisingly, calcium imaging experiments showed that AYP evokes calcium influx in only 1.5% of the total cultured DRG neurons (small-to mediumdiameter), contrasting with the broad expression pattern of PAR-4 in small-to large-diameter neurons (47%). This discrepancy may be due to the different approaches employed in this study, i.e., immunohistochemistry (ex-vivo) versus calcium imaging (in-vitro); as protein expression does not always translate in to functional responses. Of all AYP responsive neuros, 31% and 11% were respectively responsive to only the TRPV1 agonist or the TRPA1 agonist. In addition, 54% of the AYP-sensitive neurons were sensitive to both compounds. Thus, of all PAR-4 expressing DRG neurons, 85% express TRPV1, 61% express TRPA1 and 54% express both channels. Next, we stimulated cultured Trpv1 -/and Trpa1 -/mouse DRG neurons with AYP and found that AYP response is lost in Trpv1 -/but not Trpa1 -/--derived DRG neurons.
The absence of any AYP responsive DRG neurons from Trpv1 -/mice is surprising given that a small percentage of the AYP-responsive neurons appeared to be sensitive to AITC but not capsaicin. However, in these experiments, wild-type neurons were challenged with AITC before capsaicin, raising the possibility that AITC either desensitized TRPV1 or masked any subsequent response that may have been evoked by capsaicin.
Current studies have reported both additional and contrary roles for TRPV1 and TRPA1 channels in the response to different pruritogens (Fernandes et al., 2013; Wilson et al., 2011) . We investigated the in vivo contribution of TRPV1 and TRPA1 receptors to AYP-induced itch.
Whilst TRPV1 deletion or antagonism (by SB366791) clearly diminished this response, conflicting results were found when assessing the role of TRPA1 in this model. Indeed, treatment with the selective TRPA1 antagonist HC-030031 reduced PAR-4 mediated itch. However, no reduction in scratching behavior was observed in Trpa1 -/mice and the response appeared to be augmented. It is possible these different results are due to compensatory mechanisms in Trpa1 -/mice. Interestingly, although the sample sizes are small, the percentage of AYP-responsive DRG neurons was slightly higher in preparations from Trpa1 -/than from wild-type mice. Indeed, the existence of compensatory mechanisms in TRPA1 -/mice was previously suggested in a study by Petrus and collaborators (2007) . This study compared the hyperalgesic responses of TRPA1 -/mice with those treated with a selective TRPA1 antagonist, AP18. AP18-treated mice exhibited less CFA-induced hyperalgesia than mice lacking TRPA1. The authors attributed the compensatory changes in TRPA1 -/mice to possible changes in TRPV4 but not TRPV1 expression in skin cells and DRG, a hypothesis that remains unclear.
Although a central effect was suggested for SB366791 following its systemic administration (Fernandes et al., 2011) , to our knowledge, no studies have investigated the ability of HC-030031 to cross the blood brain barrier when systemically administered. However, it is possible that based on the pharmacologic properties of HC-030031 (see the PubChem Public Chemical Database), this compound may be able to penetrate the BBB, although the extent to which this happens is not completely known at this time. Thus, these drugs may be acting at both central and peripheral levels in order to inhibit AYP-induced itch. Indeed, in addition to afferent sensory fibers, TRPV1 and TRPA1 are also expressed on skin mast cells and keratinocytes (Biro and Kovacs, 2009; Buch et al., 2013; Oh et al., 2013) . Although a neuronal role has been proposed for TRP channels in itch, non-neuronal TRPA1 was recently implicated in this phenomenon (Fernandes et al., 2013) . Thus, we can suggest that TRPV1/TRPA1-expressing pruriceptive fibers, as well as skin non-neuronal cells, mediate AYP-induced scratching behavior.
SP is a neuropeptide present in TRPV1/TRPA1-expressing sensory neurons and has been implicated in itch transmission through its NK1 receptor at both peripheral and spinal sites (Akiyama et al., 2010; Andoh et al., 1998) . Here, we show that AYP-induced itch is reduced by NK1 receptor antagonism (by FK888), suggesting that SP is released upon sensitization/activation of TRP channels by the PAR-4 agonist. Indeed, SP was found to be expressed on pruriceptive neurons together with TRPV1 or TRPA1 channels (Liu et al., 2009; Sun and Chen, 2007; Imamachi et al., 2009; Wilson et al., 2013) . SP release may occur at both peripheral and central levels as TRPV1 activation can cause its release at both sites and FK888 was suggested to cross the BBB (Rudd et al., 1999; Steagall et al., 2012; Willcockson et al., 2010) .
Taken together, our findings suggest that itch-like behavior induced by PAR-4 agonist is dependent on the action of AYP on skin sensory neurons and perhaps on non-neuronal cells. In turn, this may trigger the activation of TRPV1 and TRPA1 channels, as well as the possible release of SP and GRP, transmitting the pruriceptive signal to the CNS. Overall, our data suggest that PAR-4 selective antagonists can constitute interesting tools for the attenuation of chronic itch, which remains a challenge to treat in the clinical practice. However, future studies addressing the intracellular pathways connecting the activation of PAR-4 and TRPV1/TRPA1 sensitization are of importance to further understand the pathophysiology of itch, and remain to be investigated.
Materials and Methods
Animals
Female adult CD1 mice (8-10 weeks old) from the Universidade Federal de Santa Catarina) were used. Additionally, female mice (8-12 weeks old) either WT C57BL/6/J, TRPV1knockout [Trpv1 -/-; C57BL/6 background (Costa et al., 2008) ] or TRPA1-knockout [Trpa1 -/-; C57BL/6J background (Andersson et al., 2013) ] were used. Mice were kept in a climatically controlled environment with ad libitum access to food and water and were acclimatized in the procedure room for 1 h before the experiments. 
Scratching behavior
The experiments were performed as previously described (Costa et al., 2010) . Mice 
Immunohistochemistry analysis
PAR-4 expression in the mouse skin and on DRG neurons was assessed by immunofluorescence staining followed by confocal microscopy. Anaesthetized animals were perfused with saline followed by 4% PFA phosphate buffer. Mouse rostral back skin samples (~1.5 cm 2 ) and DRGs from cervical and thoracic regions were collected. Skin samples were embedded in paraffin and sectioned (4 µm). DRGs samples were fixed in 4% PFA, cryopreserved in 30% sucrose, embedded in Tissue-Tek (Sakura Finetek, Torrance, CA) and sectioned (16 µm) at -15 o C on a cryostat (Leica, Heidelberg, Germany). Slices were incubated overnight at 4°C with PAR-4 (1:100; Santa Cruz Biotechnology, Santa Cruz, CA), protein gene product 9.5 (PGP 9.5) (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) or gastrin releasing peptide (GRP) (1:1000;
Immunostar Inc., Hudson, WI) antibodies, followed by incubation with secondary antibodies conjugated to Alexa Fluor-568 (1:750) or Alexa Fluor-488 (1:400) (Molecular Probes, Invitrogen, New York, NY) at room temperature for 3h. A series of images from different focal planes within the DRG section were collected into a single file (e.g. z-series), using confocal microscopy (Leica, Heidelberg, Germany). In DRG slices, the number of PAR-4 + , GRP + or PAR-4 + /GRP + neurons was determined with NIH ImageJ 1.36b imaging software (NIH, Bethesda, MD). Images from three random fields per section of skin samples were evaluated and captured as described above.
Cell culture and intracellular [Ca 2+ ] measurements
DRG neurons were obtained and prepared from adult WT, Trpv1 -/or Trpa1 -/female C57BL6/J mice as previously described (Andersson et al., 2012; Bevan and Winter, 1995) .
Isolated neurons were cultured in MEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 50 ng/ml NGF (Promega, Southampton, UK) for less than 24 hours before experimentation.
Cultured DRG neurons were loaded with 2.5 µM Fura-2 AM (Molecular Probes, Paisley, UK) in the presence of 1 mM probenecid for ∼1 hr. The dye loading and subsequent experiments were performed in a saline solution (pH 7.4) containing (in mM) 140 NaCl, 5 KCl, 10 glucose, 10 HEPES, 2 CaCl 2 , and 1 MgCl 2 . AYP (200 µM) was applied to cells by local continuous microperfusion of this solution through a fine tube placed very close to the cells being studied. TRP channel expression in individual neurons was tested functionally by sequential application of the agonists for TRPV1 (capsaicin, 1 µM; Sigma-Aldrich, UK) and TRPA1 (allyl isothiocyanate (AITC), 50 µM; Sigma-Aldrich, UK). All neurons were finally identified by the increase in intracellular calcium concentration evoked by depolarization with 50mM KCl.
Experiments were conducted at 35°C. Images of a group of cells were captured every 1-2 sec using 340 and 380 nm excitation wavelengths with emission measured at >510 nm with a microscope based imaging system (PTI, New Jersey). Analyses of emission intensity ratios at 340 nm/380 nm excitation (R, in individual cells) were performed using the Image Master suite of software. Effect of the pre-treatment with pyrilamine, methysergide, gabexate mesylate or combination of these drugs (at the same doses used as 4 single treatments) on the scratching behavior induced by AYP, histamine, serotonin or trypsin in mice. The data represent the mean ± 5 SEM (n = 6 per group). Significant differences (*p<0.05, Student's t test) were indicated, as compared with the vehicle-treated group. 6 
Figure legends
